Company intelligence / Profile preview
KalVista Pharmaceuticals
- Ownership
- Public · KALV
- Employees
- ~130
- Development stage
- Other
Overview
Sebetralstat demonstrated positive results in pivotal Phase III clinical trials for on-demand treatment of hereditary angioedema. It offers an oral alternative to injectable therapies and has received Fast Track and Orphan Drug Designations from the FDA. Regulatory filings are underway globally; if approved it will be the first oral on-demand HAE therapy worldwide.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Small molecules (oral protease inhibitors, specifically kallikrein inhibitors)
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on KalVista Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KalVista Pharmaceuticals.